Court: United States District Court, District of New Jersey

Leadership Position: Settlement Class Co-Lead Counsel

Result: $35 million settlement with one defendant

WBE served as Interim Co-Lead Counsel for a class of end-payor plaintiffs in a case against Pfizer Inc. and other defendants. Plaintiffs alleged violations of antitrust and consumer protection laws in connection with Pfizer’s blockbuster cholesterol drug Lipitor, once the best-selling drug of all time.

On Monday, June 3, 2024, United States District Judge Peter G. Sheridan of the District of New Jersey certified separate settlement classes of consumers and third-party payors that paid for or reimbursed prescriptions of brand or generic Lipitor and granted preliminary approval of a $30 million class action settlement to resolve antitrust claims against Pfizer Inc., one of two defendants in the case. WBE was appointed as Co-Lead Counsel for the Settlement Classes.